Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | KIF11 | P52732 | 9/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8858901 | 1.00 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL14856630 | 1.00 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL5051055 | 1.00 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8648265 | 1.00 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL30676990 | 0.90 | CA1 (0.65) | CA4LTA4HCA12CA1CA2 | |
| SCHEMBL12708677 | 0.89 | CA4 (0.52) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL408834 | 0.89 | CA4 (0.52) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL11365690 | 0.87 | CA4 (0.50) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL10112758 | 0.86 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL7021665 | 0.84 | CA4 (0.56) | CA4LTA4HKIF11KCNH2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119743231-A | Apparatus, system, and method for communicating unequal modulation and coding scheme information | 英特尔公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119544146-A | Apparatus and method for pre-FEC padding | 英特尔公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119265192-A | Compound of modified nucleotide monomer and application of compound in RNAi (ribonucleic acid interference) medicament | 纳肽得(青岛)生物医药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-118786654-A | Apparatus, system, and method for communication of MMWAVE physical layer (PHY) protocol data unit (PPDU) according to MMWAVE (MMWAVE) channelization scheme | 英特尔公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118525498-A | Apparatus, system and method for channel sounding over wide channel bandwidths | 英特尔公司 | 2024-08-20 | — | — | CN | disclosed |
| US-7276598-B2 | Phosphorylation reagents for improved processes to convert terminal hydroxyl groups of oligonucleotides into phosphate monoesters | SIGMA-ALDRICH CO. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20040230047-A1 | Coupling phosphoramidites; phosphates removable in one deprotection step; solid phase synthesis | PROLIGO, LLC (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230047-A1 | Coupling phosphoramidites; phosphates removable in one deprotection step; solid phase synthesis | DIMT1, RNGTT, ADAR | CA4 1320/4885LTA4H 4005/4885KIF11 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.